Showing 111-120 of 9252 results for "".
- GLP-1 Receptor Agonists Not Linked to Increased Melanoma Risk in T2Dhttps://practicaldermatology.com/news/glp-1-receptor-agonists-not-linked-to-increased-melanoma-risk-in-t2d/2488105/GLP-1 receptor agonist (GLP-1RA) therapy was not associated with an increased risk of melanoma among adults with type 2 diabetes (T2D) in a large target trial emulation published in Diabetes, Obesity and Metabolism. GLP-1RA Use and Skin Cancer Risk Investigators used TriN
- Treatment Sessions Linked to ABNOM Clearance in Laser Meta-Analysishttps://practicaldermatology.com/news/treatment-sessions-linked-to-abnom-clearance-in-laser-meta-analysis/2488080/Treatment session number was more strongly associated with clearance of acquired bilateral nevus of Ota-like macules (ABNOM) than whether patients received picosecond (PS) or Q-switched (QS) laser treatment, according to a new study. Published in Lasers in Medical Science, the ana
- Merz Aesthetics Announces FDA Clearance of Ultherapy PRIME for Knee Skin Laxityhttps://practicaldermatology.com/news/merz-aesthetics-announces-fda-clearance-of-ultherapy-prime-for-knee-skin-laxity/2488072/The US Food and Drug Administration (FDA) has cleared Ultherapy PRIME (Merz Aesthetics) to improve the appearance of skin laxity on the knees, according to an announcement from the company. Merz Aesthetics said the clearance makes Ultherapy PRIME the first energy-based aesthetic device wit
- Study: Reddit Upvotes May Not Reflect Quality of Rosacea Advicehttps://practicaldermatology.com/news/study-reddit-upvotes-may-not-reflect-quality-of-rosacea-advice/2488056/A study of Reddit’s r/Rosacea community examined what users discuss and whether engagement differed according to how closely recommendations aligned with National Rosacea Society (NRS) standard management options. Treatment Experiences Dominate Rosacea Discussions Investigators an
- Abrocitinib Responses Maintained Through Week 72 in JADE REALhttps://practicaldermatology.com/news/abrocitinib-responses-maintained-through-week-72-in-jade-real/2488053/New research suggests that flexible abrocitinib dosing under conditions designed to simulate clinical practice was associated with improvements through Week 72 among observed patients with moderate-to-severe atopic dermatitis (AD). Researchers for the JADE REAL trial enrolled 312 patients
- FDA Approves Tudriqev Plus Nivolumab for Advanced Melanomahttps://practicaldermatology.com/news/fda-approves-tudriqev-plus-nivolumab-for-advanced-melanoma/2488043/The FDA has granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg; Replimune, Inc.) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma whose disease progressed on a programmed death receptor-1 (PD-1)–blocking antibody-based regimen, according
- Study Validates Rapid Screening Tool for Plastic Surgery Meta-analyseshttps://practicaldermatology.com/news/study-validates-rapid-screening-tool-for-plastic-surgery-meta-analyses/2488009/A newly published study suggests that a simple three-question screening tool may help clinicians quickly identify low-quality meta-analyses without relying on lengthy methodological assessments. In a study published in the
- Fractional CO₂ Laser-Assisted Methotrexate Rivals 5-FU in Stable Vitiligohttps://practicaldermatology.com/news/fractional-co-laser-assisted-methotrexate-rivals-5-fu-in-stable-vitiligo/2487990/Topical methotrexate (MTX) delivered through fractional CO₂ laser (FCL) demonstrated efficacy and safety comparable to laser-assisted 5-fluorouracil (5-FU) for stable, nonsegmental vitiligo, according to a study published in Derm
- Meta-Analysis: Comparable Overall Outcomes With Lasers and Chemical Peels for Skin Rejuvenationhttps://practicaldermatology.com/news/meta-analysis-vcomparable-overall-outcomes-with-lasers-and-chemical-peels-for-skin-rejuvenation/2487992/A systematic review and meta-analysis published in Plastic and Reconstructive Surgery found that laser resurfacing and chemical peeling provide comparable overall efficacy for skin rejuvenation, although each modality demon
- Lebrikizumab Meets Primary Endpoints in Phase 3 ADorable-1 Trial for Pediatric Atopic Dermatitishttps://practicaldermatology.com/news/lebrikizumab-meets-primary-endpoints-in-phase-3-adorable-1-trial-for-pediatric-atopic-dermatitis/2487891/Lebrikizumab demonstrated significant improvements in disease severity and symptoms in infants, children, and adolescents with moderate-to-severe atopic dermatitis (AD), according to Week 16 results from the phase 3 ADorable-1 trial presented at the 2026 Society f